Adverse events ‐ treatment emergent · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
Urtoxazumab (3.0 mg/kg) showed no clear difference in adverse events ‐ treatment emergent compared with placebo (low certainty).
1 finding from 1 review
Adverse events ‐ serious · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
Urtoxazumab (3.0 mg/kg) may leads to lower adverse events ‐ serious compared with placebo (low certainty).
1 finding from 1 review
Adverse events · patients with diarrhoea due to Shiga toxin‐producing E. coli
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Neurological complications · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
It is very uncertain whether urtoxazumab (3.0 mg/kg) changes neurological complications compared with placebo (very low certainty).
1 finding from 1 review
Death (any cause) · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
It is very uncertain whether urtoxazumab (3.0 mg/kg) changes death (any cause) compared with placebo (very low certainty).
1 finding from 1 review
Incidence of HUS · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
It is very uncertain whether urtoxazumab (1.0 mg/kg) changes incidence of HUS compared with placebo (very low certainty).
1 finding from 1 review
Adverse events ‐ treatment emergent · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
Urtoxazumab (1.0 mg/kg) showed no clear difference in adverse events ‐ treatment emergent compared with placebo (low certainty).
1 finding from 1 review
Adverse events ‐ serious · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
1 finding from 1 review
Neurological complications · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
It is very uncertain whether urtoxazumab (1.0 mg/kg) changes neurological complications compared with placebo (very low certainty).
1 finding from 1 review
Death (any cause) · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
It is very uncertain whether urtoxazumab (1.0 mg/kg) changes death (any cause) compared with placebo (very low certainty).
1 finding from 1 review
Neurological complications · patients with diarrhoea due to Shiga toxin‐producing E. coli
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death (any cause) · patients with diarrhoea due to Shiga toxin‐producing E. coli
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of HUS · patients with diarrhoea due to Shiga toxin‐producing E. coli
1 finding from 1 review
Adverse events · patients with diarrhoea due to Shiga toxin‐producing E. coli
It is very uncertain whether bovine colostrum changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
Neurological complications · patients with diarrhoea due to Shiga toxin‐producing E. coli
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death (any cause) · people with CKD who are overweight or obese
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cardiovascular events · people with CKD who are overweight or obese
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events ‐ weight loss · people with CKD who are overweight or obese
1 finding from 1 review
Body‐mass index (BMI) · people with CKD who are overweight or obese
1 finding from 1 review
Waist circumference · people with CKD who are overweight or obese
1 finding from 1 review